Catheter-Based Renal Denervation in HTN: Key Points
- Authors:
- Vukadinovic D, Lauder L, Kandzari De, et al.
- Citation:
- Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis. Circulation 2024;Oct 2:[Epub ahead of print].
The following are key points to remember from a systematic review and meta-analysis on the effects of catheter-based renal denervation in patients with hypertension (HTN):
- In a meta-analysis of 10 sham-controlled trials that included 2,478 patients, renal denervation decreased 24-hour systolic blood pressure (BP) by 4.4 mm Hg and office systolic pressure by 6.6 mm Hg, both of which were statistically significant.
- This BP drop was seen in patients with both medication treated and untreated HTN.
- Renal denervation appeared to be safe, with no notable risk of renal impairment or vascular injury.
- All methods of denervation (alcohol mediated, ultrasound, or radiofrequency) were effective.
- The BP drop was similar to that generally seen in about one-half medication. Clinicians must be thoughtful in determining whether renal denervation is the best way to achieve this BP drop, particularly in obese patients in whom glucagon-like peptide-1 inhibition may also give a similar antihypertensive effect.
- Future studies may identify subgroups of patients, such as younger patients, for whom renal denervation may potentially be more effective than in older patients.
- This study had maximum follow-up of 6 months. It is unknown if reinnervation will occur if patients were followed for a longer period of time.
- More experience is necessary to establish where renal denervation will be of best use in a clinician’s armamentarium. Patients are often intolerant of medications, hesitant to take medications, and can also have HTN resistant to even the best medical regimen. Similarly, a patient’s antihypertensive regimen can frequently be adjusted by specialists trained specifically in HTN management in a way that can often yield considerable improvement in BP.
- Patients with secondary causes of HTN were excluded from these trials.
Clinical Topics: Prevention, Hypertension, Invasive Cardiovascular Angiography and Intervention
Keywords: Antihypertensive Agents, Blood Pressure, Denervation, Hypertension
< Back to Listings